In a research article '3D Nano-scale Imaging by Plasmonic Brownian Microscopy' published today in Nanophotonics, the team around Prof. Xiang Zhang from the University of California in Berkeley demonstrate a method for meeting this challenge with stunning properties.
About one third of all medicine binds to the same type of receptor in the human body. An estimated 3 percent of the population have receptors of this type that are so genetically different that they are predisposed to altered, ineffective or adverse responses to medicine, a new study from the University of Copenhagen and the MRC Laboratory of Molecular Biology in Cambridge shows.
Scientists of the Friedrich Schiller University Jena, Germany succeeded in developing an efficient method to treat mucoviscidosis. Crucial are nanoparticles that transport the antibiotics more efficiently to their destination. First of all, the active particles need to have a certain size to be able to reach the deeper airways and not to bounce off somewhere else before. Ultimately, they have to penetrate the thick layer of mucus on the airways as well as the lower layers of the bacteria biofilm.
Recently developed computational strategies could help realize the promise of peptide-based drugs. Researchers were able to sample the diverse landscape of shapes that peptides can form as a guide for designing the next generation of stable, potent, selective drugs. They compiled a library of peptide scaffolds upon which drug candidates might be designed. Their methods also can be used to design additional custom peptides with arbitrary shapes on demand.
Salk scientists develop new approach to identify important undiscovered functions of proteins.
A novel approach published in Science by a collaborative team of researchers from the Wyss Institute, Arizona State University, and Autodesk for the first time enables the design of complex single-stranded DNA and RNA origami that can autonomously fold into diverse, stable, user-defined structures.
Drug discovery could be significantly accelerated thanks to a new high precision machine-learning model, developed by an international collaboration of researchers, including the University of Warwick.
Scientists have created computationally designed protein assemblies, that display some functions normally associated with living things, in the search for ways to transport therapeutic cargo into specific types of cells without using viruses as vehicles. These encapsulate their own RNA genomes and evolve new traits in complex environments. They are synthetic versions of the protein shells that viruses use to protect and deliver materials. The synthetic proteins evolved better RNA packaging, resistance against degrading enzymes in blood and longer circulation time.
Survival benefits of many cancer drug combinations are not due to drug synergy, but to a form of "bet hedging." Combination treatment gives each patient multiple chances of responding to at least one drug, increasing measures of survival within patient populations. Findings suggest new ways to interpret clinical trial data, identify truly synergistic drug pairings and improve the design of combination therapies.
A new methodology enables the investigation of a large number of structurally conserved enzymes belonging to the Fe(II)/2-oxoglutarate-dependent dioxygenase superfamily.